Overview and Scope
Age-related macular degeneration (AMD) refers to a progressive eye condition in which the macula, which is located at the center of the retina, deteriorates over time in individuals with AMD, leading to a decline in central vision. It is due to aging. The therapy options for age-related macular degeneration include regular eye exams, lifestyle changes, and particular nutritional supplements.
Sizing and Forecast
The age-related macular degeneration market size has grown strongly in recent years. It will grow from $9.17 billion in 2023 to $9.9 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to aging population demographics, changing lifestyles and environmental factors, genetic predisposition, increased awareness and early diagnosis, advancements in diagnostic techniques..
The age-related macular degeneration market size is expected to see strong growth in the next few years. It will grow to $13.1 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to research in genetics and biomarkers, emerging therapeutic modalities, telemedicine and remote monitoring, patient advocacy and education.. Major trends in the forecast period include personalized medicine approaches, innovations in retinal imaging technologies, emergence of sustained drug delivery systems, clinical trials for investigational therapies, collaborations for research and development..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/age-related-macular-degeneration-global-market-report
Segmentation & Regional Insights
The age-related macular degeneration market covered in this report is segmented –
1) By Type: Wet Age-Related Macular Degeneration (AMD), Dry Age-Related Macular Degeneration (AMD)
2) By Drug: Eylea, Lucentis, Avastin, Other Products
3) By Route Of Administration: Intravenous, Intravitreal
4) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy, Online Pharmacy
North America was the largest region in the global age-related macular degeneration market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10845&type=smp
Major Driver Impacting Market Growth
Rising age-related macular degeneration (AMD) prevalence is expected to propel the growth of the age-related macular degeneration (AMD) market going forward. Age-related macular degeneration (AMD) is a progressive eye condition affecting the macula, a small part of the retina responsible for central vision. Age-related macular degeneration (AMD) treatments support patients suffering from retinal disorders by minimizing the severity of the disease condition. For instance, in February 2023, according to the reports shared by Optimaxa., a UK-based laser eye treatment specialist, age-related macular degeneration (AMD) affected 196 million individuals globally and is expected to reach 288 million in 2040, accounting for 8.7 percent of the world’s population. Therefore, rising age-related macular degeneration (AMD) prevalence is driving the age-related macular degeneration market.
Key Industry Players
Major companies operating in the age-related macular degeneration market report are F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Amgen Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., AbbVie Inc., Outlook Therapeutics Inc., Biogen Inc., Samsung Bioepis Co. Ltd., Allergan plc, Biocon Ltd., Bio-Thera Biopharmaceutical Co. Ltd., AstraZeneca plc, Acucela Inc., Ophthotech Corporation, Kodiak Sciences Inc., REGENXBIO Inc., Alkahest Inc., Opthea Limited, Apellis Pharmaceuticals Inc., Graybug Vision Inc., IVERIC bio Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., Tyrogenex Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., I-Mab Biopharma Co. Ltd., pSivida Corp., Clearside Biomedical Inc., SciFluor Life Sciences LLC, Lineage Cell Therapeutics Inc.
The age-related macular degeneration market report table of contents includes:
1. Executive Summary
2. Age-Related Macular Degeneration Market Characteristics
3. Age-Related Macular Degeneration Market Trends And Strategies
4. Age-Related Macular Degeneration Market – Macro Economic Scenario
5. Global Age-Related Macular Degeneration Market Size and Growth
.
.
.
31. Global Age-Related Macular Degeneration Market Competitive Benchmarking
32. Global Age-Related Macular Degeneration Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Age-Related Macular Degeneration Market
34. Age-Related Macular Degeneration Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report
https://www.thebusinessresearchcompany.com/report/dry-eye-medication-global-market-report
https://www.thebusinessresearchcompany.com/report/post-traumatic-stress-disorder-therapeutics-global-market-report
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
